ANILERIDINE PHOSPHATE

US Previously Marketed

First approved in 1957

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N2O2.H3O4P
Molecular Weight	450.4651
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OP(O)(O)=O.CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=FLQCEKVTYABVSH-UHFFFAOYSA-N

InChI=1S/C22H28N2O2.H3O4P/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;1-5(2,3)4/h3-11H,2,12-17,23H2,1H3;(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C22H28N2O2
Molecular Weight	352.4699
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H3O4P
Molecular Weight	97.9952
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278

Aniledrine is a narcotic pain reliver. The drug was prescribed as an analgesic in anaesthesia (Leritine brand name), however, it is no longer available on the market. Although the exact mechanism is not fully understood, aniledrine appears to elicit its action by binding to endorphine receptors in CNS.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278	Curative		Approved 8583	LERITINE Approved Use Unknown

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% OTHER https://go.drugbank.com/drugs/DB00913			ANILERIDINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
450 mg multiple, oral Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439	unhealthy, 41 Health Status: unhealthy Age Group: 41 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/7541439	Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium Sources: https://pubmed.ncbi.nlm.nih.gov/7541439

AEs

AE	Significance	Dose	Population
Delirium	Disc. AE	450 mg multiple, oral Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7541439	unhealthy, 41 Health Status: unhealthy Age Group: 41 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/7541439

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:61203	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:61203
ZINC	ZINC000000608179	http://zinc15.docking.org/substances/ZINC000000608179

PubMed

Title	Date	PubMed
Synthesis, characterization and antimicrobial properties of a Co(II)-phthalylsulfathiazolate complex.	2010-12	20526731
Metabolic fate of orally administered phyllodulcin in rats.	2004-09	15387672
Electronic-topological study of the structure-activity relationships in a series of piperidine morphinomimetics.	2002-08	12171562
Anileridine-induced delirium.	1995-05	7541439
Qualitative differences in effects of opioids in man: preliminary evidence for multiple mechanisms of analgesic action.	1986-05	3755241
Contact dermatitis to anileridine.	1980-12	6894270

Patents

Sample Use Guides

In Vivo Use Guide

Aniledrine is administred either orally (in form of hydrochloride salt)

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:23:39 GMT 2025` Edited by `admin` on `Mon Mar 31 21:23:39 GMT 2025`
Record UNII	3584484N8V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANILERIDINE PHOSPHATE [MART.]

Preferred Name

English

ANILERIDINE PHOSPHATE

Common Name

English

Anileridine phosphate [WHO-DD]

Common Name

English

ANILERIDINE PHOSPHATE [ORANGE BOOK]

Common Name

English

LERITINE PHOSPHATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241